EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

TLE1 drives EGFR-TKI resistance in EGFR-mutant lung adenocarcinoma through epithelial to mesenchymal transition

Ma Carmela Dela Cruz, Xin Yao, Nasir Roberts, Prince Iheukwumere, Alana Carmouche, Paul Mark Medina, Hector Biliran

Biochemical and Biophysical Research Communications · 2025-08 · 775 · 152146

DOI: 10.1016/j.bbrc.2025.152146 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2025-08. Verfasst von Ma Carmela Dela Cruz und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, Xavier University of Louisiana, New Orleans, LA, USA; Biological Models Laboratory, Department of Biochemistry and Molecular B…. Hauptthemen laut MEDLINE: Epithelial-Mesenchymal Transition, Drug Resistance, Neoplasm, Adenocarcinoma of Lung, Lung Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Philippines Council for Health Research and Development, Department of Science and Technology, Ministry of Science and Technology, India, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted therapies using EGFR-TKIs are fundamental treatment options for cases of lung adenocarcinoma harboring sensitizing mutations in EGFR. However, tumor progression to acquired resistance significantly hinders long-term efficacy. While the involvement of transcription factors in EGFR-TKI resistance has been extensively investigated, the contribution of transcriptional co-repressors like Transducin-Like Enhancer of Split 1 (TLE1) remains largely unexplored. This study identifies TLE1 as a mediator of insensitivity to EGFR-TKI treatment in lung adenocarcinoma positive for EGFR mutation. Analysis of patient data indicated that elevated TLE1 level was associated with unfavorable survival outcomes among patients with EGFR-mutant LUAD, underscoring its clinical significance. In vitro, specifically in PC9 and HCC827 cells, exogenous TLE1 expression promoted epithelial-mesenchymal transition (EMT) and reduced cellular response to the EGFR-TKIs gefitinib and osimertinib. Conversely, sole downregulation of endogenous TLE1 expression partially restored drug sensitivity in PC9GR and HCC827GR acquired resistance cell line models. At a mechanistic level, TLE1 functions as a co-repressor, interacting with ZEB1 to suppress E-cadherin expression, a key EMT marker, thereby facilitating resistance. This paper provides first evidence of TLE1 driven EMT-associated failure of EGFR-TKI treatment particularly in EGFR-mutant LUAD through its co-repressor activity. These results underscore the previously underappreciated role of transcriptional co-repressors in therapeutic resistance and position TLE1 as a promising prognostic and therapeutic target. Interventions targeting the TLE1-ZEB1 interaction may represent a new approach to mitigate EGFR-TKI resistance and improve outcomes for patients with EGFR-mutant LUAD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epithelial-Mesenchymal TransitionDrug Resistance, NeoplasmAdenocarcinoma of LungLung NeoplasmsProtein Kinase InhibitorsCo-Repressor ProteinsHumansErbB ReceptorsCell Line, TumorMutationZinc Finger E-box-Binding Homeobox 1GefitinibAcrylamidesGene Expression Regulation, NeoplasticAniline CompoundsIndolesPyrimidines

Stichwörter der Autor:innen

E-cadherinEGFR-TKI resistanceEMTTLE1ZEB1

Substanzen

ErbB ReceptorsEGFR protein, humanTLE1 protein, humanProtein Kinase InhibitorsCo-Repressor ProteinsosimertinibZinc Finger E-box-Binding Homeobox 1GefitinibZEB1 protein, humanAcrylamides

Autor:innen und Institutionen

  • Department of Biology, Xavier University of Louisiana, New Orleans, LA, USA; Biological Models Laboratory, Department of Biochemistry and Molecular Biology, College of Medicine, University of the Philippines Manila, Man…
  • Department of Biology, Xavier University of Louisiana, New Orleans, LA, USA.
  • Biological Models Laboratory, Department of Biochemistry and Molecular Biology, College of Medicine, University of the Philippines Manila, Manila City, Philippines.
  • Department of Biology, Xavier University of Louisiana, New Orleans, LA, USA. Electronic address: hbiliran@xula.edu.

Förderung

  • Philippines Council for Health Research and Development
  • Department of Science and Technology, Ministry of Science and Technology, India
  • National Institutes of Health

Zitieren

APA

Dela Cruz, M. C., Yao, X., Roberts, N., Iheukwumere, P., Carmouche, A., Medina, P. M., & Biliran, H. (2025). TLE1 drives EGFR-TKI resistance in EGFR-mutant lung adenocarcinoma through epithelial to mesenchymal transition. Biochemical and Biophysical Research Communications, 775, 152146. https://doi.org/10.1016/j.bbrc.2025.152146

Vancouver

Dela Cruz MC, Yao X, Roberts N, Iheukwumere P, Carmouche A, Medina PM, et al. TLE1 drives EGFR-TKI resistance in EGFR-mutant lung adenocarcinoma through epithelial to mesenchymal transition. Biochemical and Biophysical Research Communications. 2025;775:152146. doi:10.1016/j.bbrc.2025.152146

BibTeX
@article{DelaCruz2025,
  author = {Dela Cruz, Ma Carmela and Yao, Xin and Roberts, Nasir and Iheukwumere, Prince and Carmouche, Alana and Medina, Paul Mark and Biliran, Hector},
  title = {TLE1 drives EGFR-TKI resistance in EGFR-mutant lung adenocarcinoma through epithelial to mesenchymal transition},
  journal = {Biochemical and Biophysical Research Communications},
  year = {2025},
  volume = {775},
  pages = {152146},
  doi = {10.1016/j.bbrc.2025.152146}
}
Kostenlos starten →